# A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab

> **NCT00379431** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 9 (actual)

## Conditions studied

- Early and Severe Systemic Sclerosis

## Interventions

- **DRUG:** Administration of rituximab and methylprednisolone

## Key facts

- **NCT ID:** NCT00379431
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11-27
- **Primary completion:** 2009-02-02
- **Final completion:** 2009-02-02
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00379431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00379431, "A Protocol Based Treatment for Early and Severe Systemic Sclerosis With (Anti-CD20), Rituximab". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00379431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*